Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).

Proceedings of the National Academy of Sciences of the United States of America - 23 Sept 2014

Komarova Natalia L, Burger Jan A, Wodarz Dominik

Abstract excerpt

The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib is given orally on a continuous schedule and induces durable remissions in the majority of CLL patients. However, a small proportion of patients initiall...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Agammaglobulinaemia Tyrosine Kinase
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Proteins

Share to Piperidines

Share to Protein-Tyrosine Kinases

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 25201956
DOI: 10.1073/pnas.1409362111
PMCID: PMC4183279

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25201956-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).PMID 25201956Read ↗

Epigenomic evolution in chronic lymphocytic leukaemia cells from patients treated with ibrutinib and showing disease progressionSemantic proximity Read ↗

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.Semantic proximity Read ↗

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaSemantic proximity Read ↗

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.Semantic proximity Read ↗

Drug resistance in cancer: Principles of emergence and preventionSemantic proximity Read ↗

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemiaSemantic proximity Read ↗

Preventing clonal evolutionary processes in cancer: Insights from mathematical models.Semantic proximity Read ↗

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Semantic proximity Read ↗

Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design.Semantic proximity Read ↗

Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.Semantic proximity Read ↗

Ibrutinib treatment of CLL: the cancer fights back.Semantic proximity Read ↗

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.